Abstract: The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.

Abstract: The present invention pertains to a method for the identification of genetic variants that are associated with the severity of an infectious disease. The invention further pertains to a set of genetic factors associated with the severity of Human respiratory syncytial virus (HRSV) infection, for example in human infants. The genetic polymorphisms identified according to the present invention are for use in the diagnostic of infectious diseases and patient stratification in order to avoid or reduce the occurrence of fatal events during infection or to elect the most appropriate therapeutic approach to treat the disease.

Abstract: The invention pertains to the use of lonafarnib or any analog or derivative thereof for the treatment of a viral disease characterized by a viral entry into a host cell via a viral fusion glycoprotein (F-protein). In particular, the invention provides treatments of human respiratory syncytial virus (HRSV) caused diseases comprising the administration (use) of lonafarnib or its analogs or derivatives, as well as pharmaceutical compositions comprising lonafarnib or its analogs and derivates.

Abstract: The present invention relates to a host cell, which comprises under the control of a heterologous promoter a polynucleotide comprising a nucleotide sequence encoding a polypeptide capable of synthesizing a polysaccharide consisting of a dimeric repeating unit as well as to a vaccine composition comprising such host cell. Furthermore, either such host cell or a polypeptide expressed by such host cell is used for the production of a polysaccharide consisting of a dimeric repeating unit which may be used as a glycoconjugate vaccine.

Abstract: The invention provides an ex-vivo method, i.e. an in vitro method, for genetically modifying cells of a vascularised tissue, which can be anorgan, during normothermic or subnormothermic perfusion without damaging the tissue or its cells due to oxygen undersupply. The method enables keeping the vascularised tissue at normothermic or subnormothermic conditions over a sufficient period of time to genetically modify the cells e.g. with viral vectors.

Abstract: A system includes a stent Including a first end for arrangement on a tubal ostium, a second end for arrangement on a bony isthmus of smaller diameter than a diameter of the first end, and adjacent to the second end a length portion of decreasing diameter. The system further includes an applicator for placement of the stent in a Eustachian tube. The applicator has a proximal end for handling the applicator and a distal end for receiving the stent. The distal end includes an inner part which has at least one area that is plastically deformable by manual force, for adaptation to a patient-dependent access angle of the Eustachian tube, and an outer tube which surrounds the inner part at a radial distance and which delimits an annular gap for receiving the stent, with the stent in the annular gap made of nitinol and being self-expanding.

Abstract: The present invention relates to a long non-coding RNA as a therapeutic target in cardiac disorders.

Abstract: An accessory kit is provided for interventional procedures using a magnetic resonance imaging scanner. The accessory kit includes a patient support and an electrical connection adapter. The patient support has a first end proximal and a second end distal to the scanner. The distal end is configured to create a space to accommodate a clinician, such as narrowing of the distal end or at least one cutout on a side of the distal end. The electrical connection adapter interfaces with the scanner and a scanner table. The accessory kit is configured so that when the proximal end is extended into the scanner bore, the distal end extends outside the bore. The narrowed width and/or cutout(s) of the exposed distal end and the extended gap between the scanner and scanner table create space on at least one side of the patient support that a clinician may use to access a patient.

Abstract: The invention relates to methods for generating an aerosol by nebulization of a composition comprising polyclonal immunoglobulin (Ig). The selection of an efficient membrane nebulizer and a composition optimized for nebulization with such membrane nebulizer results in a particularly efficient method of generating an aerosol for administration of Ig to the respiratory tract.

Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 22, preferably selected from SEQ ID NOs 1 to 3; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 23 to 42. The present invention also relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 23 to 42; and/or (ii) a compound inhibiting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 22, preferably selected from SEQ ID NOs 1 to 3.

Abstract: The present invention relates to cells engineered to express at least one cytokine and at least one antigen which induces the self differentiation of dendritic cell (DC) progenitor cells into functional antigen-presenting induced DC (iDC). Moreover, therapeutic uses of said iDC for regenerating the immune system after transplantation of hematopoietic stem cells are disclosed. Said iDC are also useful for generating mice with a functional endogenously regenerated humanized immune system producing antigen-specific T and B cell responses which can be used as animal models for the study of the human adaptive immune responses.

Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii)a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.

Abstract: The invention relates to a prosthesis for implantation into a living body in the form of a magnetic artificial joint, in particular an artificial shoulder joint, comprising: a) a first prosthesis member comprising a socket member, b) a second prosthesis member comprising a head member, c) one of the socket member and the head member is at least partially composed as a permanent magnet and the other one of the socket member and the head member is at least partially composed of a magnetic material, or the socket member and the head member are both at least partially composed as a permanent magnet, d) the socket member comprises a recess on a surface side to be coupled with the head member, the recess comprising a concavely contoured contact surface, e) the head member comprises a projection on a surface side to be coupled with the socket member, the projection comprising a convexly contoured contact surface, f) the convexly contoured contact surface is adapted to the concavely contoured contact surface, such th

Abstract: The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g.

Abstract: The present invention relates to an analytical in vitro process for predicting the therapeutic effectiveness of at least one pharmaceutical compound in the treatment of leukemia and/or lymphoma, the process analysing the transmembrane potential of mitochondria in cells isolated from a patient by quantification of fluorescence emitted from a dye indicating induction of apoptosis.

Abstract: A method for processing CT imaging data includes providing CT imaging data obtained at two x-ray energy levels in a first respiratory phase, preferably in an inhalation phase, of the subject and providing second CT imaging data obtained at two x-ray energy levels in a second respiratory phase, preferably in an exhalation phase, of the subject. The method may include reconstructing first regional perfusion blood volume (PBV) imaging data from the provided first CT imaging data, reconstructing second regional PBV imaging data from the provided second CT imaging data, reconstructing first virtual non-contrast (VNC) imaging data from the provided first CT imaging data, reconstructing second VNC imaging data from the provided second CT imaging data, determining a transformation function for registering the first and second reconstructed VNC imaging data, and registering the first and second reconstructed VNC imaging data by applying the transformation function.

Abstract: The present application provides for the use of S100A8 or S100A9 homodimer or S100A8/A9 heterodimer in the prevention or treatment of a NF-?B-associated postnatal inflammatory disorder in a newborn subject. Moreover, the present invention relates to a pharmaceutical composition comprising S100A8 or S100A9 homodimer or S100A8/A9 heterodimer and an in vitro method for evaluating the risk of a newborn subject for developing a NF-?B-associated postnatal inflammatory disorder.

Abstract: The invention relates to a shape-adaptive medical implant having at least one actuator, which the implant can be changed from a first implant geometry to a second implant geometry, the implant having a different geometric shape in the second implant geometry from that in the first implant geometry, wherein the actuator has a swellable chemical substance which swells when supplied with liquid, and wherein the implant which is designed to supply liquid present outside the implant to the swellable chemical substance. The invention also relates to the use of an electrical signal source.

Abstract: The invention relates to an irradiation device and a corresponding method for irradiating a radiation absorbing medium, as well as a hearing aid device and a laser surgery device comprising such an irradiation device. A radiation source is configured to generate one or more pulses of electromagnetic radiation and to irradiate the medium with the one or more pulses of electromagnetic radiation. A control unit is configured to control the radiation source such that the time course of the power or intensity of at least one pulse of the one or more pulses of electromagnetic radiation exhibits a rising slope and/or a falling slope, wherein the rising slope and/or falling slope has a maximum gradient which is smaller than a predetermined gradient value, whereby a generation of optoacoustic waves in the medium in response to the rising slope or falling slope, respectively, is avoided or significantly reduced.

Abstract: The present invention refers to an oligonucleotide which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders.